About: A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
Creator	Chiu, Charles Zhou, Xin Wilson, Michael Byrnes, James Elledge, Susanna Glasgow, Jeff Leung, Kevin Lim, Shion Loudermilk, Rita Lui, Irene Wells, James
Source	MedRxiv; Medline; PMC
abstract	As SARS-CoV-2 continues to spread around the world, there is an urgent need for new assay formats to characterize the humoral response to infection. Convalescent serum is being used for treatment and for isolation of patient-derived antibodies. However, currently there is not a simple means to estimate serum bulk neutralizing capability. Here we present an efficient competitive serological assay that can simultaneously determine an individual’s seropositivity against the SARS-CoV-2 Spike protein and estimate the neutralizing capacity of anti-Spike antibodies to block interaction with the human angiotensin converting enzyme 2 (ACE2) required for viral entry. In this ELISA-based assay, we present natively-folded viral Spike protein receptor binding domain (RBD)-containing antigens via avidin-biotin interactions. Sera are then supplemented with soluble ACE2-Fc to compete for RBD-binding serum antibodies, and antibody binding quantified. Comparison of signal from untreated serum and ACE2-Fc-treated serum reveals the presence of antibodies that compete with ACE2 for RBD binding, as evidenced by loss of signal with ACE2-Fc treatment. In our test cohort of nine convalescent SARS-CoV-2 patients, we found all patients had developed anti-RBD antibodies targeting the epitope responsible for ACE2 engagement. This assay provides a simple and high-throughput method to screen patient sera for potentially neutralizing anti-Spike antibodies to enable identification of candidate sera for therapeutic use.
has issue date	2020-05-29(xsd:dateTime)
bibo:doi	10.1101/2020.05.27.20114652
bibo:pmid	32511506
has license	no-cc
sha1sum (hex)	a0f7ecfbaf316567515425d820f24ab30c98b5c7
schema:url	https://doi.org/10.1101/2020.05.27.20114652
resource representing a document's title	A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
has PubMed Central identifier	PMC7273274
has PubMed identifier	32511506
schema:publication	medRxiv
resource representing a document's body	covid:a0f7ecfbaf316567515425d820f24ab30c98b5c7#body_text
is schema:about of	named entity 'ESTIMATE' named entity 'CONTAINING' named entity 'REVEALS' named entity 'SPIKE' named entity 'OUR' named entity 'PROVIDES' named entity 'Convalescent serum' named entity 'antibodies' named entity 'humoral response' named entity 'serological assay' named entity 'serum' named entity 'Spike protein' named entity 'biotin' named entity 'antibodies' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'SARS-CoV-1' named entity 'molecular weight' named entity 'preprint' named entity 'IgG' named entity 'ACE2' named entity 'fusion construct' named entity 'serum' named entity 'ACE2' named entity 'IgM' named entity 'epitope' named entity 'biotin' named entity 'peer review' named entity 'RBD' named entity 'serum' named entity 'preprint' named entity 'antibodies' named entity 'biotin' named entity 'dimeric' named entity 'serum' named entity 'ACE2' named entity 'serum' named entity 'IgG' named entity 'NeutrAvidin' named entity 'infection' named entity 'ACE2' named entity 'antigen' named entity 'viruses' named entity 'antigen' named entity 'ACE2' named entity 'antibodies' named entity 'IgA' named entity 'serum' named entity 'antigens' named entity '60 minutes' named entity 'RBD' named entity 'medRxiv' named entity 'serum' named entity 'Thermo Fisher' named entity 'biotin' named entity 'Tween 20' named entity 'RBD' named entity 'biotin' named entity 'SARS-CoV-2' named entity 'adsorbed' named entity 'vaccines' named entity 'RBD' named entity 'UCSF' named entity 'NeutrAvidin' named entity 'NeutrAvidin' named entity 'DNA sequence' named entity 'ACE2' named entity 'Protein' named entity 'serum' named entity 'antigens'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software